Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 78c, Beats on Revenue; Offers FY23 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Provision for income taxes: 0
Today's EPS Names:
VIVO, OCCI, ALZN, More
Financial Fact:
Provision for income taxes: 0
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.49, $0.78 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $100.37 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2023 revenue of $390-395 million, versus the consensus of $389.1 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Canaccord Starts L1 Group Ltd (L1G:AU) at Buy
- Amneal gets FDA approval for lanreotide injection, launches immediately
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
